Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, OBIO trades at $3.98 with a market cap of $238.33M and a P/E ratio of -3.57. OBIO moved +0.13% today. Year to date, OBIO is -6.13%; over the trailing twelve months it is +34.92%. Its 52-week range spans $2.20 to $6.50. Analyst consensus is strong buy with an average price target of $13.40. Rallies surfaces OBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
OBIO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. OBIO recently traded at $3.98. Market cap is $238.33M. P/E ratio is -3.57. Revenue is $33.48M.
| Metric | Value |
|---|---|
| Price | $3.98 |
| Market Cap | $238.33M |
| P/E Ratio | -3.57 |
| EPS | $-1.11 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.50 |
| 52-Week Low | $2.20 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $33.48M |
| Net Income | $-52.70M |
| Gross Margin | 99.43% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $33.48M | $-52.70M | $-1.11 |
| 2024 | $2.64M | $-61.02M | $-1.66 |
| 2023 | $2.76M | $-49.12M | $-1.48 |
6 analysts cover OBIO: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.40.